Emphysema News and Research

Latest Emphysema News and Research

Experts applaud the EU Presidency for establishing a transatlantic task force to address antibiotic resistance

Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.

7 Nov 2009

CHANTIX/CHAMPIX raises hope for quitting smoking

New study results showed that 42.3 percent of smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with 8.8 percent of those given placebo (p<0.0001). These findings were presented by investigators at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP).

5 Nov 2009

SBRT stops the growth of cancer for 98% of patients with NSCLC

Stereotactic body radiation therapy (SBRT) stopped the growth of cancer at its original site in the lung for three years among nearly 98 percent of patients with early non-small cell lung cancer (NSCLC) who are unable to have the cancer surgically removed, according to an updated three-year study presented November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

3 Nov 2009

Medico's Hirata to distribute Broncus Technologies' LungPoint system and Yield catheters in Japan

Broncus Technologies, Inc., a medical device company focused on developing and commercializing innovative solutions for lung diseases, announced today at the American College of Chest Physicians CHEST 2009 meeting that it has entered into an exclusive agreement with Medico's Hirata as the sole distributor of their LungPoint system and Yield catheters in Japan.

3 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

NHLBI survey results reveal COPD awareness continues to grow in the United States

Awareness of COPD-chronic obstructive pulmonary disease-continues to grow in the United States, according to national survey results released today by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.

3 Nov 2009

John C. Lincoln Hospital first to use commercially-available LungPoint system

Broncus Technologies, Inc., a medical device company focused on developing minimally-invasive innovations for lung diseases, announced today at the American College of Chest Physicians CHEST 2009 meeting that John C. Lincoln Hospital in Phoenix is the first hospital in the U.S. to use the commercially-available LungPoint system.

2 Nov 2009

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

Sosei Group announces Phase III trials update on NVA237 and QVA149

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), announces that the Phase III trials with NVA237, which commenced in June 2009, are proceeding to plan. Initiation of Phase III studies with QVA149 is now expected to occur during 2010.

22 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

Talecris Biotherapeutics' PROLASTIN-C receives FDA approval

Talecris Biotherapeutics (Nasdaq: TLCR) today received approval from the U.S. Food and Drug Administration for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more concentrated version of PROLASTIN® produced using advances in manufacturing technology.

19 Oct 2009

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Berinert® C1-Esterase Inhibitor, Human for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE), a rare and serious genetic disorder, in adult and adolescent patients. Berinert is the first and only therapy approved for this indication in the U.S.

12 Oct 2009

CSL Behring LEAD program invites grant requests from organizations assisting people with rare diseases

CSL Behring, a global leader in the plasma-protein biotherapeutics industry, is calling for grant requests through its Local Empowerment for Advocacy Development (LEAD) program. The LEAD program awards funds to United States patient organizations that assist people with rare diseases in advocating for continued access to health care and life-saving plasma protein therapies.

7 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

Respiragene test for lung cancer motivates smokers to quit smoking

Smokers who learn their personal risk of lung cancer through gene-based risk assessment are more likely to be motivated to quit their habit, according to Dr. W. Jeffrey Allard, clinical affairs director of Synergenz Bioscience Ltd.

1 Oct 2009

Electronic medical records cut costs and helps medical facilities to provide quality healthcare to patients

Electronic medical records have been a cornerstone of the successful health care formula prescribed by Dr. Richard Merkin, CEO for Heritage Provider Network. HPN and its 25 medical facilities in California and Healthcare Partners IPA in New York have been eliminating waste and cutting costs while providing quality healthcare to their patients for the past 30 years by focusing on the importance of integrating electronic medical records.

22 Sep 2009

American Lung Association applauds EPA’s decision to reduce threat from dangerous air pollutant

Today the Administrator of the U.S. Environmental Protection Agency, Lisa Jackson, announced that the Agency will embark on a formal review of the national air quality standard for ozone, a decision that offers the opportunity to finally protect the health of millions of Americans from the most widespread and one of the most dangerous air pollutants.

17 Sep 2009

Genetically removing the osteopontin protein prevents lung diseases

In a development that could lead to a novel approach to the treatment of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD).

16 Sep 2009

Novartis presents Phase II results of the QVA149 bronchodilator for the treatment of COPD

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) announce that Novartis have presented the results of their two Phase II studies evaluating the efficacy, safety and tolerability of QVA149 at the annual congress of the European Respiratory Society (ERS) in Vienna.

16 Sep 2009

Proteostasis Therapeutics to use GeneGo's MetaCore integrated software

GeneGo, Inc., the leading systems biology tools company, announced today that Proteostasis Therapeutics has licensed its data mining and analysis platform, MetaCore. Proteostasis Therapeutics is the first company dedicated to the discovery of novel small molecule therapeutics based upon understanding the body's Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases.

8 Sep 2009